C3J Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Inglewood CA United States (2005)
Status: Acquired by AmpliPhi Biosciences Corporation (2019)

Organization Overview

First Clinical Trial
2014
NCT02044081
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

C3 Jian, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: C3J Therapeutics (0) Acquired (1)

tgaavcf (1 trial)

Drugs in Phase 2 Trials (4)

Key: C3J Therapeutics (0) Acquired (4)

c16g2 (7 trials)

tgaac09 (2 trials)

tgaac94 (2 trials)

tgaag76 (1 trial)

Drugs in Phase 1 Trials (1)

Key: C3J Therapeutics (0) Acquired (1)

ab-sa01 (2 trials)

Drugs in Other Trials (1)

Key: C3J Therapeutics (0) Acquired (1)

ab-pa01 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dental Caries (Phase 2)

Overview

  • Highest Phase: None
  • # of Trials: 16
  • # of Trial APIs: 7